State of Tennessee Treasury Department acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the medical research company’s stock, valued at approximately $2,263,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Swiss National Bank grew its holdings in shares of Bio-Rad Laboratories by 1.5% in the second quarter. Swiss National Bank now owns 34,707 shares of the medical research company’s stock valued at $7,855,000 after purchasing an additional 500 shares during the period. Eagle Asset Management Inc. grew its holdings in shares of Bio-Rad Laboratories by 1.8% in the second quarter. Eagle Asset Management Inc. now owns 30,782 shares of the medical research company’s stock valued at $6,966,000 after purchasing an additional 540 shares during the period. Pacad Investment Ltd. purchased a new stake in shares of Bio-Rad Laboratories in the second quarter valued at about $113,000. Chicago Equity Partners LLC purchased a new stake in shares of Bio-Rad Laboratories in the second quarter valued at about $1,064,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 4.8% in the second quarter. Principal Financial Group Inc. now owns 89,043 shares of the medical research company’s stock valued at $20,151,000 after purchasing an additional 4,084 shares during the period. 62.84% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/18/state-of-tennessee-treasury-department-takes-position-in-bio-rad-laboratories-inc-bio.html.

Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 227.91 on Monday. Bio-Rad Laboratories, Inc. has a one year low of $154.89 and a one year high of $242.79. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 450.42 and a beta of 0.93. The company has a 50 day moving average of $221.09 and a 200-day moving average of $217.09.

A number of brokerages recently issued reports on BIO. TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price objective for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective for the company. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $228.80.

In related news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares in the company, valued at approximately $444,774.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 28.29% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.